Citations

Mayo Clinic

Showing 10 of 108523 citations.

Global and regional mortality statistics of nipah virus from 1994 to 2023: a comprehensive systematic review and meta-analysis
Vasudevan, Srivatsa Surya , Subash, Arun, Mehta, Fena, Kandrikar, Tiba Yamin , Khan, Kaif, Khanduja, S., Raavi, Lekhya , Gondaliya, Piyush , Subash, Arun, Desai, Rupak , Khanduja, Sneha, Pitliya, Aakanksha , Kanagala, Sai Gautham

Pathogens and Global Health | July 20, 2024 | Volume: 118 | Issue: 6 | Pages: 471-480

10.1080/20477724.2024.2380131 | PMID 39030703 Get It

Treatment of lichen sclerosus with hydroxychloroquine: a Mayo Clinic experience
Akpala, Christeebella O. , Tekin, Burak , Torgerson, Rochelle R. , Wetter, David A. , Nguyen, Giang Huong , Akpala, Christeebella O , Nguyen, Giang H

International Journal of Dermatology | July 20, 2024 | Volume: 63 | Issue: 10 | Pages: No page available

10.1111/ijd.17394 | PMID 39032011 Get It

AbstractBackgroundThere is a dearth of studies investigating the efficacy of hydroxychloroquine in the treatment of either anogenital lichen sclerosus or extragenital lichen sclerosus, a condition that, if left untreated, could lead to a greater degree of scarring and malignant transformation.ObjectiveThis study aims to analyze the demographic characteristics, clinicopathological features, treatment response, and outcomes of patients diagnosed with either anogenital or extragenital lichen sclerosus who received hydroxychloroquine therapy.MethodsA retrospective analysis was conducted involving 70 patients diagnosed with lichen sclerosus who underwent treatment with hydroxychloroquine at our institution between 2018 and 2023.ResultsAmong the cohort, 67 patients were female, and 3 were male. Extragenital lichen sclerosus was diagnosed in 23 patients, with 16 exhibiting concomitant morphea overlap. Itching was the predominant clinical presentation (67%). A notable proportion of patients (36%) had a connective tissue disorder, prompting hydroxychloroquine therapy. Among the 30 patients treated solely for lichen sclerosus, 21 demonstrated response and 9 had no response. From a broader comparison of response to hydroxychloroquine, the overall anogenital response rate was 84.6% as opposed to 50% in extragenital lichen sclerosus. The median time to initial response was 4 months. Adverse effects, predominantly mild, were observed in 10 (14.3%) patients.LimitationThis study is constrained by its retrospective nature and reliance on data from a single center, resulting in a limited sample size.ConclusionHydroxychloroquine demonstrates promise as a therapeutic option for anogenital lichen sclerosus because of its favorable response rates and low incidence of adverse effects. However, further investigations, including larger‐scale or prospective studies, are imperative to ascertain its definitive efficacy.
Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial
Peris, Ketty , Inocencio, Timothy J. , Stratigos, Alexander , Lewis, Karl D. , Eroglu, Zeynep , Chang, Anne Lynn S. , Ivanescu, Cristina, Fury, Matthew G., Chen, C., Quek, Ruben G.W. , Sekulić, Aleksandar , Inocencio, Timothy J , Sekulic, Aleksander , Chen, Chieh-I

Cancer Medicine | July 20, 2024 | Volume: 13 | Issue: 14 | Pages: No page available

10.1002/cam4.7360 | PMID 39031963 Get It

AbstractBackgroundA phase 2 cemiplimab study (NCT03132636) demonstrated a 24.1% objective response rate in patients diagnosed with metastatic basal cell carcinoma (mBCC) who were not candidates for continued hedgehog inhibitor (HHI) therapy due to intolerance to previous HHI therapy, disease progression while receiving HHI therapy, or having not better than stable disease on HHI therapy after 9 months. Here, health‐related quality of life (QoL) for this patient population is reported.MethodsAdult patients with mBCC were treated with intravenous cemiplimab at a dose of 350 mg every 3 weeks for 5 treatment cycles of 9 weeks/cycle then 4 treatment cycles of 12 weeks/cycle. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life‐Core 30 (QLQ‐C30) and Skindex‐16 questionnaires at baseline and Day 1 of each cycle. Across Cycles 2 to 9, the overall change from baseline was analyzed using a mixed model with repeated measures. Responder analyses determined clinically meaningful improvement or deterioration (changes ≥10 points) or maintenance across all scales.ResultsPatients reported low symptom burden and moderate‐to‐high functioning at baseline. Maintenance for QLQ‐C30 global health status (GHS)/QoL and across all functioning and symptom scales was indicated by overall mean changes from baseline. Clinically meaningful improvement or maintenance was reported at Cycle 2 for GHS/QoL (77%), functioning scales (77% to 86%), and symptom scales (70% to 93%), with similar proportions of improvement or maintenance at Cycles 6 and 9, excluding fatigue. On the Skindex‐16, clinically meaningful improvement or maintenance was reported across the emotional, symptom, and functional subscales, in 76%–88% of patients at Cycle 2, which were generally maintained at Cycles 6 and 9. Overall mean changes from baseline showed maintenance across these subscales.ConclusionsThe majority of patients treated with cemiplimab reported improvement or maintenance in GHS/QoL and functioning while maintaining a low symptom burden.
Postintubation hypotension following rapid sequence intubation with full- vs reduced-dose induction agent
Mattson, Alicia E , Brown, Caitlin S. , Cole, Kristin, Haefke, Brandon , Cabrera, Daniel , Mara, Kristin C. , Sandefur, Benjamin J. , Mara, Kristin C , Cabrera, Daniel

American Journal of Health-System Pharmacy | July 20, 2024 | Volume: 82 | Issue: 3 | Pages: e148-e156

10.1093/ajhp/zxae217 | PMID 39046917 Get It

Abstract Purpose Rapid sequence intubation (RSI) is a common emergency department (ED) procedure with an associated complication of postintubation hypotension (PIH). It has not been clearly established whether the selection and dose of induction agent affect risk of PIH. The objective of this study was to determine the incidence of PIH in patients receiving full-dose compared to reduced-dose induction agent for RSI in the ED. Methods This was a health system–wide, retrospective cohort study comparing incidence of PIH based on the induction medication and dose given for RSI in the ED. Patients were included if they underwent RSI from July 1, 2018, through December 31, 2020, were 18 years of age or older, and received etomidate or ketamine. A reduced dose was defined as a ketamine dose of 1.25 mg/kg or less and an etomidate dose of 0.2 mg/kg or less. Results A total of 909 patients were included in the final analysis, with most receiving etomidate (n = 764; 84%) and a smaller number receiving ketamine (n = 145; 16%). Patients who received ketamine had a higher mean pre-intubation shock index (full dose, 1.08; reduced dose, 1.04) than those who received etomidate (full dose, 0.89; reduced dose, 0.92) (P ≤ 0.001). Reduced doses of induction agent were observed for 107 patients receiving etomidate (14.0%) and 60 patients receiving ketamine (41.4%). Patients who received full-dose ketamine for induction had the highest rate of PIH (n = 31; 36.5%), and the difference was statistically significant compared to patients receiving reduced-dose ketamine (16.7%; P = 0.021) and full-dose etomidate (22.8%; P = 0.010). Conclusion We observed that full-dose ketamine was associated with the highest rate of PIH; however, this group had the poorest baseline hemodynamics, confounding interpretation. Our results do not support broad use of a reduced-dose induction agent.
Evaluation of knowledge‐based planning models for male pelvic CBCT‐based online adaptive radiotherapy on conventional linear accelerators
Tegtmeier, Riley C. , Clouser, Edward , Toesca, Diego A.S. , Flakus, Mattison J. , Bashir, Sara, Kutyreff, Christopher J. , Hobbis, Dean , Harrington, Daniel P. , Smetanick, Jennifer L., Yu, Nathan Y. , Vargas, Carlos , James, Sarah E. , Rwigema, Jean‐Claude M. , Clouser, Edward L, Laughlin, Brady S. , Santos Toesca, Diego A, Hobbis, Dean , Rong, Yi , Kutyreff, Christopher J , Clouser, Edward Lee , Rong, Yi

Journal of Applied Clinical Medical Physics | July 20, 2024 | Volume: 25 | Issue: 9 | Pages: No page available

10.1002/acm2.14464 | PMID 39031902 Get It

AbstractPurposeTo assess the practicality of employing a commercial knowledge‐based planning tool (RapidPlan) to generate adapted intact prostate and prostate bed volumetric modulated arc therapy (VMAT) plans on iterative cone‐beam computed tomography (iCBCT) datasets.Methods and materialsIntact prostate and prostate bed RapidPlan models were trained utilizing planning data from 50 and 44 clinical cases, respectively. To ensure that refined models were capable of producing adequate clinical plans with a single optimization, models were tested with 50 clinical planning CT datasets by comparing dose‐volume histogram (DVH) and plan quality metric (PQM) values between clinical and RapidPlan‐generated plans. The RapidPlan tool was then used to retrospectively generate adapted VMAT plans on daily iCBCT images for 20 intact prostate and 15 prostate bed cases. As before, DVH and PQM metrics were utilized to dosimetrically compare scheduled (iCBCT Verify) and adapted (iCBCT RapidPlan) plans. Timing data was collected to further evaluate the feasibility of integrating this approach within an online adaptive radiotherapy workflow.ResultsModel testing results confirmed the models were capable of producing VMAT plans within a single optimization that were overall improved upon or dosimetrically comparable to original clinical plans. Direct application of RapidPlan on iCBCT datasets produced satisfactory intact prostate and prostate bed plans with generally improved target volume coverage/conformality and rectal sparing relative to iCBCT Verify plans as indicated by DVH values, though bladder metrics were marginally increased on average. Average PQM values for iCBCT RapidPlans were significantly improved compared to iCBCT Verify plans. The average time required [in mm:ss] to generate adapted plans was 06:09 ± 02:06 (intact) and 07:12 ± 01:04 (bed).ConclusionThis study demonstrated the feasibility of leveraging RapidPlan to expeditiously generate adapted VMAT intact prostate and prostate bed plans on iCBCT datasets. In general, adapted plans were dosimetrically improved relative to scheduled plans, emphasizing the practicality of the proposed approach.
Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS‐BAD
Lupianez‐Merly, Camille , Jencks, Kara J. , Ferber, Monique, Melo, Luma , Klinken, B. Jan‐Willem van , Kalgaonkar, Swati, Camilleri, Michael , Jencks, Kara , Dilmaghani, Saam , Camilleri, M , Ferber, Monique

Alimentary Pharmacology & Therapeutics | July 19, 2024 | Volume: 60 | Issue: 4 | Pages: 544-545

10.1111/apt.18164 | PMID 39031892 Get It

Outcomes of patients with R/R B-cell NHL and limited (
Saifi, Omran , Breen, William G. , Rule, William G., Stish, Bradley J. , Bansal, Radhika , Hathcock, Matthew , Johnston, Patrick B. , Ansell, Stephen M. , Khurana, Arushi , Ayala, Ernesto , Kharfan‐Dabaja, Mohamed A. , Peterson, Jennifer , Lester, Scott C. , Bansal, Radhika , Paludo, Jonas , Villasboas, Jose Caetano , Wang, Yucai , Moustafa, Muhamad Alhaj , Murthy, Hemant S , Kharfan-Dabaja, Mohamed A , Hoppe, Bradford S , Peterson, Jennifer L , Rosenthal, Allison , Muñoz, Javier , Lin, Yi , Paludo, Jonas , Villasboas, José C. , Wang, Yucai , Iqbal, Madiha , Moustafa, Muhamad Alhaj , Murthy, Hemant S. , Hoppe, Bradford S.

Blood Advances | July 19, 2024 | Volume: 8 | Issue: 18 | Pages: 4877-4885

10.1182/bloodadvances.2024013647 | PMID 39028948 Get It

Abstract Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is heightened in individuals with limited/localized disease before CART. This study reports on the outcomes of patients with R/R NHL and limited (<5 involved sites) disease bridged with or without radiotherapy. A multicenter retrospective review of 150 patients with R/R NHL who received CART with <5 disease sites before leukapheresis was performed. Bridging treatment, if any, was administered between leukapheresis and CART infusion. Study end points included relapse-free survival (RFS), event-free survival (EFS), and overall survival. Before CART infusion, 48 patients (32%) received bridging radiotherapy (BRT), and 102 (68%) did not. The median follow-up was 21 months. After CART infusion, BRT patients had higher objective response (92% vs 78%; P = .046) and sustained complete response rates (54% vs 33%; P = .015). Local relapse in sites present before CART was lower in the BRT group (21% vs 46%; P = .003). BRT patients had improved 2-year RFS (53% vs 44%; P = .023) and 2-year EFS (37% vs 34%; P = .039) compared with patients who did not receive BRT. The impact of BRT was most prominent in patients who had ≤2 pre-CART involved disease sites, with 2-year RFS of 62% in patients who received BRT compared with 42% in those who did not (P = .002). BRT before CART for patients with limited (<5 involved disease sites) R/R NHL improves response rate, local control, RFS, and EFS without causing significant toxicities.
Reinforcement learning‐based anatomical maps for pancreas subregion and duct segmentation
Amiri, Sepideh , Mustafaev, Tamerlan , Deufel, Christopher L. , Brandt, Erik Gudmann Steuble , Müller, Christoph , Ibragimov, Bulat , Vrtovec, Tomaž , Thomsen, Henrik S. , Sillesen, Martin , Andersen, Michael Brun

Medical Physics | July 19, 2024 | Volume: 51 | Issue: 10 | Pages: 7378-7392

10.1002/mp.17300 | PMID 39031886 Get It

AbstractBackgroundThe pancreas is a complex abdominal organ with many anatomical variations, and therefore automated pancreas segmentation from medical images is a challenging application.PurposeIn this paper, we present a framework for segmenting individual pancreatic subregions and the pancreatic duct from three‐dimensional (3D) computed tomography (CT) images.MethodsA multiagent reinforcement learning (RL) network was used to detect landmarks of the head, neck, body, and tail of the pancreas, and landmarks along the pancreatic duct in a selected target CT image. Using the landmark detection results, an atlas of pancreases was nonrigidly registered to the target image, resulting in anatomical probability maps for the pancreatic subregions and duct. The probability maps were augmented with multilabel 3D U‐Net architectures to obtain the final segmentation results.ResultsTo evaluate the performance of our proposed framework, we computed the Dice similarity coefficient (DSC) between the predicted and ground truth manual segmentations on a database of 82 CT images with manually segmented pancreatic subregions and 37 CT images with manually segmented pancreatic ducts. For the four pancreatic subregions, the mean DSC improved from 0.38, 0.44, and 0.39 with standard 3D U‐Net, Attention U‐Net, and shifted windowing (Swin) U‐Net architectures, to 0.51, 0.47, and 0.49, respectively, when utilizing the proposed RL‐based framework. For the pancreatic duct, the RL‐based framework achieved a mean DSC of 0.70, significantly outperforming the standard approaches and existing methods on different datasets.ConclusionsThe resulting accuracy of the proposed RL‐based segmentation framework demonstrates an improvement against segmentation with standard U‐Net architectures.
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone
Patidar, Kavish R. , Tu, Wanzhu , Cotter, Thomas G. , Asgharpour, Amon , Jan, Muhammad Y. , Tang, Qing , Taiwo, Moyinoluwa, Nagesh, Prashanth Thevkar , Kamath, Patrick S. , Chalasani, Naga , Nagy, Laura E. , Shah, Vijay H. , Investigators, for The AlcHepNet, Vargas, Hugo E. , Duarte‐Rojo, Andrés , Simonetto, Douglas A , Thevkar Nagesh, Prashanth , Dasarathy, Srinivasan , Kamath, Patrick S , Szabo, Gyongyi , Mitchell, Mack , Mehal, Wajahat Z , Gawrieh, Samer , Sanyal, A J , Cotter, T G , Vargas, Hugo E , Duarte-Rojo, Andres , Patidar, Kavish R , Simonetto, Douglas A. , Yu, Yunpeng , Li, Yang , McClain, Craig J. , Bataller, Ramon A , Gawrieh, Samer , Sanyal, Arun J. , Investigators, for The AlcHepNet

Hepatology | July 19, 2024 | Volume: 81 | Issue: 4 | Pages: 1256-1268

10.1097/hep.0000000000001019 | PMID 39028887 Get It

Background and Aims: In a recent trial, patients with severe alcohol-associated hepatitis treated with anakinra plus zinc (A+Z) had lower survival and higher acute kidney injury (AKI) rates versus prednisone (PRED). We characterize the clinical factors and potential mechanisms associated with AKI development in that trial. Approach and Results: Data from 147 participants in a multicenter randomized clinical trial (74 A+Z, 73 PRED) were analyzed. AKI, AKI phenotypes, and kidney injury biomarkers were compared between participants who did/did not develop AKI in the 2 treatment arms. Multivariable competing risk analyses were performed to identify baseline risk factors for incident AKI, with death treated as a competing event. Risk factors considered were age, sex, mean arterial pressure, white blood cell count, albumin, MELD, ascites, HE, and treatment arm. At baseline, no participants had AKI; 33% (n=49) developed AKI during follow-up. AKI incidence was higher in A+Z than in PRED (45% [n=33] versus 22% [n=16], p=0.001). AKI phenotypes were similar between the 2 treatment arms (p=0.361), but peak AKI severity was greater in A+Z than PRED (stage 3 n=21 [63.6%] vs. n=8 [50.0%], p=0.035). At baseline, urine-neutrophil-gelatinase–associated lipocalin levels were similar between participants who developed AKI in both treatment arms (p=0.319). However, day 7 and 14 urine-neutrophil-gelatinase–associated lipocalin levels were significantly elevated in participants treated with A+Z who developed AKI versus participants treated with PRED who developed AKI (p=0.002 and 0.032, respectively). On multivariable competing risk analysis, only A+Z was independently associated with incident AKI (subdistribution hazard ratio 2.35, p=0.005). Conclusions: AKI occurred more frequently and was more severe in participants treated with A+Z. A+Z–treated participants with AKI had higher urine-neutrophil-gelatinase–associated lipocalin, suggesting that A+Z maybe nephrotoxic in patients with severe alcohol-associated hepatitis.
Epigenetic heterogeneity hotspots in human liver disease progression
Hlady, Ryan A. , Zhao, Xia , Khoury, Louis Y. El , Wagner, Ryan T. , Luna, Aesis , Pham, Kien , Pyrosopoulos, Nikolaos T., Jain, Dhanpat , Wang, Liguo , Robertson, Keith D. , Liu, Chen , Robertson, Keith D , Wang, Liguo , El Khoury, Louis Y , Liu, Chen

Hepatology | July 19, 2024 | Volume: 81 | Issue: 4 | Pages: 1197-1210

10.1097/hep.0000000000001023 | PMID 39028883 Get It

Background and Aims: Disruption of the epigenome is a hallmark of human disease, including liver cirrhosis and HCC. While genetic heterogeneity is an established effector of pathologic phenotypes, epigenetic heterogeneity is less well understood. Environmental exposures alter the liver-specific DNA methylation landscape and influence the onset of liver cancer. Given that currently available treatments are unable to target frequently mutated genes in HCC, there is an unmet need for novel therapeutics to prevent or reverse liver damage leading to hepatic tumorigenesis, which the epigenome may provide. Approach and Results: We performed genome-wide profiling of DNA methylation, copy number, and gene expression from multiple liver regions from 31 patients with liver disease to examine their crosstalk and define the individual and combinatorial contributions of these processes to liver disease progression. We identified epigenetic heterogeneity hotspots that are conserved across patients. Elevated epigenetic heterogeneity is associated with increased gene expression heterogeneity. Cirrhotic regions comprise 2 distinct cohorts—one exclusively epigenetic, and the other where epigenetic and copy number variations collaborate. Epigenetic heterogeneity hotspots are enriched for genes central to liver function (eg, HNF1A) and known tumor suppressors (eg, RASSF1A). These hotspots encompass genes including ACSL1, ACSL5, MAT1A, and ELFN1, which have phenotypic effects in functional screens, supporting their relevance to hepatocarcinogenesis. Moreover, epigenetic heterogeneity hotspots are linked to clinical measures of outcome. Conclusions: Substantial epigenetic heterogeneity arises early in liver disease development, targeting key pathways in the progression and initiation of both cirrhosis and HCC. Integration of epigenetic and transcriptional heterogeneity unveils putative epigenetic regulators of hepatocarcinogenesis.